Calithera Biosciences, Inc. (CALA)
| Market Cap | 487.00 -90.0% |
| Revenue (ttm) | n/a |
| Net Income | -21.29M |
| EPS | -7.94 |
| Shares Out | 4.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 343 |
| Open | 0.0001 |
| Previous Close | n/a |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.0010 |
| Beta | -1.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Calithera Biosciences
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. [Read more]
News
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”).
Calithera Biosciences Annual report: Q4 2022
Calithera Biosciences has published its Q4 2022 annual report on March 31, 2023.
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of ...
Calithera Biosciences Earnings Call Transcript: Q3 2022
Calithera Biosciences Quarterly report: Q3 2022
Calithera Biosciences has published its Q3 2022 quarterly earnings report on November 14, 2022.
Calithera Biosciences Earnings release: Q3 2022
Calithera Biosciences released its Q3 2022 earnings on November 14, 2022, summarizing the period's financial results.
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 -- -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 --
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's thi...
Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate
Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small c...
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation Enrollment ongoing in Phase 2 stu...
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan M...
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 -- -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 --
Calithera Biosciences Earnings Call Transcript: Q2 2022
Calithera Biosciences Quarterly report: Q2 2022
Calithera Biosciences has published its Q2 2022 quarterly earnings report on August 15, 2022.
Calithera Biosciences Earnings release: Q2 2022
Calithera Biosciences released its Q2 2022 earnings on August 15, 2022, summarizing the period's financial results.
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's sec...
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored...
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, In...
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has f...
Calithera to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Mol...
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: ...
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Compa...
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022 Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022